HTL0009936
Sponsors
Nxera Pharma UK Limited
Conditions
Alzheimer's Disease
Phase 1
Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment
CompletedNCT02291783
Start: 2013-11-30End: 2014-07-31Updated: 2017-06-20
Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
CompletedNCT02546310
Start: 2015-10-31End: 2017-02-28Target: 54Updated: 2017-02-03